Neointimal formation following drug-eluting stents: physiology, timeline, and the influence of drug delivery systems.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Reviews in cardiovascular medicine

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 17401309
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation.

  2007cited by this paper
• Very late thrombosis after drug‐eluting stents

  2006cited by this paper
• Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials.

  2006cited by this paper
• Prevalence, Predictors, and Outcomes of Premature Discontinuation of Thienopyridine Therapy After Drug-Eluting Stent Placement: Results From the PREMIER Registry

  2006cited by this paper
• Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings.

  2006cited by this paper
• Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project.

  2006cited by this paper
• Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk.

  2006cited by this paper
• Periprocedural and late consequences of overlapping Cypher sirolimus-eluting stents: pooled analysis of five clinical trials.

  2006cited by this paper
• Intravascular ultrasound in the drug-eluting stent era.

  2006cited by this paper
• Thirty-day incidence and six-month clinical outcome of thrombotic stent occlusion after bare-metal, sirolimus, or paclitaxel stent implantation.

  2005cited by this paper
• Molecular Basis of Restenosis and Drug-Eluting Stents

  2005cited by this paper
• Maintenance of Long-Term Clinical Benefit With Sirolimus-Eluting Coronary Stents: Three-Year Results of the RAVEL Trial

  2005cited by this paper
• Differential Response of Delayed Healing and Persistent Inflammation at Sites of Overlapping Sirolimus- or Paclitaxel-Eluting Stents

  2005cited by this paper
• Drug-eluting stent thrombosis: results from a pooled analysis including 10 randomized studies.

  2005cited by this paper
• Thrombosis Modulates Arterial Drug Distribution for Drug-Eluting Stents

  2005cited by this paper
• Inflammation, atherosclerosis, and coronary artery disease.

  2005cited by this paper
• Late angiographic stent thrombosis (LAST) events with drug-eluting stents.

  2005cited by this paper
• Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry.

  2005cited by this paper
• Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents.

  2005cited by this paper
• Preclinical restenosis models and drug-eluting stents: still important, still much to learn.

  2004cited by this paper
• Local Gene Transfer of phVEGF-2 Plasmid by Gene-Eluting Stents: An Alternative Strategy for Inhibition of Restenosis

  2004cited by this paper
• First human experience with the 17-beta-estradiol-eluting stent: the Estrogen And Stents To Eliminate Restenosis (EASTER) trial.

  2004cited by this paper
• Specific binding to intracellular proteins determines arterial transport properties for rapamycin and paclitaxel.

  2004cited by this paper
• A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease.

  2004cited by this paper
• Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent.

  2004cited by this paper
• Pathological Mechanisms of Fatal Late Coronary Stent Thrombosis in Humans

  2003cited by this paper
• TAXUS I: Six- and Twelve-Month Results From a Randomized, Double-Blind Trial on a Slow-Release Paclitaxel-Eluting Stent for De Novo Coronary Lesions

  2003cited by this paper
• Left main coronary artery fistula exiting into the right atrium

  2003cited by this paper
• Tissue Engineering Therapy for Cardiovascular Disease

  2003cited by this paper
• Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.

  2003cited by this paper
• Inflammation in atherosclerosis

  2002cited by this paper
• Arterial Ultrastructure Influences Transport of Locally Delivered Drugs

  2002cited by this paper
• Inflammation and Restenosis in the Stent Era

  2002cited by this paper
• Estrogen‐eluting, phosphorylcholine‐coated stent implantation is associated with reduced neointimal formation but no delay in vascular repair in a porcine coronary model

  2002cited by this paper
• A comparison of four stent designs on arterial injury, cellular proliferation, neointima formation, and arterial dimensions in an experimental porcine model

  2001cited by this paper
• Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model

  2001cited by this paper
• Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans.

  2000cited by this paper
• Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months.

  2000cited by this paper
• Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries.

  1998cited by this paper
• Rapamycin inhibits vascular smooth muscle cell migration.

  1996cited by this paper
• Endogenous cell seeding. Remnant endothelium after stenting enhances vascular repair.

  1996cited by this paper
• Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene.

  1995cited by this paper
• Rapamycin-FKBP inhibits cell cycle regulators of proliferation in vascular smooth muscle cells.

  1995cited by this paper
• How does taxol stabilize microtubules?

  1995cited by this paper
• Differential neointimal response to coronary artery injury in pigs and dogs. Implications for restenosis models.

  1994cited by this paper
• Generalized model of restenosis after conventional balloon angioplasty, stenting and directional atherectomy.

  1993cited by this paper

• Selective Temporary Stent-Assisted Coil Embolization for Intracranial Wide-Necked Small Aneurysms Using Solitaire AB Retrievable Stent

  2018cites this paper
• Quantitative analysis of stenting effects on cellular response

  2015cites this paper
• Nitric Oxide Prevents Aortic Neointimal Hyperplasia by Controlling Macrophage Polarization

  2014cites this paper
• Use of stent-assisted coil embolization for the treatment of wide-necked aneurysms: A systematic review

  2013cites this paper
• Gene targeting in ischemic heart disease and failure: translational and clinical studies.

  2013cites this paper
• In vivo PEG modification of vascular surfaces for targeted delivery.

  2012cites this paper
• Application of nitric oxide in drug discovery and development

  2011cites this paper
• Very late changes in the dilated lesion following coronary balloon angioplasty: a 17 year serial quantitative angiographic study.

  2009cites this paper
• Coronary aneurysm and very late stent thrombosis formation associated with sirolimus-eluting stent implantation.

  2009cites this paper
• Analytical sensitivity limits for lateral flow immunoassays.

  2008cites this paper